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Article

Type I interferon is selectively
required by dendritic cells for immune
rejection of tumors

of Pathology and Immunology, 2Division of Radiological Sciences, and 3Howard Hughes Medical Institute,
School of Medicine, Washington University in St. Louis, St. Louis, MO 63110
4Institute for Experimental Infection Research, TWINCORE, 30625 Hannover, Germany

The Journal of Experimental Medicine
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Cancer immunoediting is the process whereby the immune system suppresses neoplastic
growth and shapes tumor immunogenicity. We previously reported that type I interferon
(IFN-/) plays a central role in this process and that hematopoietic cells represent critical
targets of type I IFN’s actions. However, the specific cells affected by IFN-/ and the
functional processes that type I IFN induces remain undefined. Herein, we show that type I
IFN is required to initiate the antitumor response and that its actions are temporally
distinct from IFN- during cancer immunoediting. Using mixed bone marrow chimeric mice,
we demonstrate that type I IFN sensitivity selectively within the innate immune compartment is essential for tumor-specific T cell priming and tumor elimination. We further show
that mice lacking IFNAR1 (IFN-/ receptor 1) in dendritic cells (DCs; Itgax-Cre+Ifnar1f/f
mice) cannot reject highly immunogenic tumor cells and that CD8+ DCs from these mice
display defects in antigen cross-presentation to CD8+ T cells. In contrast, mice depleted of
NK cells or mice that lack IFNAR1 in granulocytes and macrophage populations reject these
tumors normally. Thus, DCs and specifically CD8+ DCs are functionally relevant targets of
endogenous type I IFN during lymphocyte-mediated tumor rejection.
CORRESPONDENCE
Robert D. Schreiber:
schreiber@
immunology.wustl.edu
Abbreviations used: 5-FU,
5-fluorouracil; FLC, fetal liver cell;
HSC, hematopoietic stem cell;
MCA, 3-methylcholanthrene;
pDC, plasmacytoid DC; polyI:C,
polyinosinic:polycytidylic acid.

The ability of the immune system to function as
an extrinsic tumor suppressor and effectively
eliminate, control, and/or sculpt developing
tumors forms the basis of the cancer immunoedit
ing hypothesis (Shankaran et al., 2001; Dunn
et al., 2002, 2004). There is strong experimental
support for all three phases of cancer immuno
editing, elimination, equilibrium, and escape, and
many of the key cellular mediators and immune
effector molecules involved in host protection
from tumor development have been identified
(Dunn et al., 2006; Smyth et al., 2006; Koebel
et al., 2007; Schreiber et al., 2011; Vesely et al.,
2011). The IFNs, both type I (IFN-/) and
type II (IFN-), have emerged as critical compo
nents of the cancer immunoediting process, and
work is ongoing to define their respective roles in
promoting antitumor immune responses.
M.S. Diamond and M. Kinder contributed equally to this
paper.
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Early studies supporting the existence of
cancer immunoediting revealed an important
function for IFN- in suppressing tumor de
velopment in models of both tumor transplan
tation and primary tumor induction (Dighe
et al., 1994; Kaplan et al., 1998; Shankaran
et al., 2001; Street et al., 2001, 2002). Specifi
cally, IFN- was found to induce effects on
both tumor cells (Dighe et al., 1994; Kaplan
et al., 1998; Shankaran et al., 2001; Dunn et al.,
2005) and host cells (Mumberg et al., 1999;
Qin and Blankenstein, 2000; Qin et al., 2003).
Subsequently, an essential function for endog
enous type I IFN in cancer immunoediting was
established (Dunn et al., 2005; Swann et al.,
2007). Gene-targeted mice lacking the type I
© 2011 Diamond et al. This article is distributed under the terms of an
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six
months after the publication date (see http://www.rupress.org/terms). After six months
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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factor (CD8+ DCs and CD103+ DCs, hereafter referred to as
CD8+ lineage DCs) was shown to play an important role in
cross-presenting viral and tumor antigens, and mice lacking
these cells fail to reject highly immunogenic unedited sarcomas
(Hildner et al., 2008; Edelson et al., 2010). However, it remains
unknown whether the cross-presenting activity of these cells re
quires type I IFN to induce tumor immunity.
In the current study, we have investigated the host cell tar
gets of endogenous type I IFN during the rejection of highly
immunogenic, unedited tumors. We demonstrate that IFN-/
acts early during the initiation of the immune response and

Figure 1. Early requirement for IFN-/ during rejection of highly
immunogenic tumor cells. (A) Untreated WT and Rag2/ mice or WT
mice injected i.p. with either IFNAR1-specific MAR1-5A3 mAb or isotype
control GIR-208 mAb 1 d prior were s.c. injected with 106 H31m1 tumor
cells, and tumor size was measured over time. Data represent mean tumor
diameter ± SEM of 12–16 mice per group from at least three independent
experiments. (B–D) WT mice were injected with 106 H31m1 cells (at day 0)
and treated beginning on the indicated day with MAR1-5A3 (B), IFN-–
specific H22 mAb (C), or a mixture of anti-CD4/anti-CD8/anti–IFN- mAbs
GK1.5/YTS-169.4/H22 (D), and tumor growth was monitored. For each time
point, groups of mice were treated in parallel with the respective isotypematched control mAb, and the data are presented as percent tumor growth
over the control group. Results are from two to four experiments with 14–20
(ctrl/MAR1-5A3), 10–20 (ctrl/H22), or 6–11 (ctrl/cocktail) WT mice per
group. The kinetics of tumor growth in individual mice is shown in Fig. S1.
Type I IFN effects during tumor rejection | Diamond et al.
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IFN receptor developed more carcinogen-induced primary
tumors than WT control mice (Dunn et al., 2005; Swann
et al., 2007), and antibody-mediated blockade of the IFN-/
receptor in WT hosts abrogated rejection of immunogenic
transplanted tumors (Dunn et al., 2005). The activity of
endogenous type I IFN was mediated not by its direct effects
on the tumor but by its actions on host cells, specifically on
hematopoietic-derived host cells (Dunn et al., 2005). Collec
tively, these findings highlight a difference between the
antitumor activities of the IFNs, wherein tumor cell respon
siveness to IFN- but not IFN-/ and host cell responsive
ness to both IFN- and IFN-/ are crucial for tumor
rejection. However, the relevant host cell targets and anti
tumor functions of IFN-/ and IFN- remain undefined
because of the nearly ubiquitous expression of IFN-/ and
IFN- receptors and the pleiotropic effects they induce.
Although initially defined by their antiviral activity, the type
I IFNs are potent immunomodulators that shape host immunity
through direct actions on innate and adaptive lymphocytes. The
enhancement of NK cell cytotoxicity by IFN-/ in the setting
of viral infection was one of the earliest such effects to be recog
nized (Biron et al., 1999). Type I IFN directly augments NK
cell–mediated killing of virally infected or transformed cells and
indirectly promotes the expansion and survival of NK cells
through IL-15 induction (Nguyen et al., 2002). Furthermore, in
models of NK cell–dependent tumor rejection, host cell respon
siveness to IFN-/ was shown to be important for control of
tumor growth and metastasis (Swann et al., 2007). Type I IFN
can also act directly on T and B lymphocytes to modulate their
activity and/or survival. Treatment with IFN-/ in vitro pro
longed the survival of activated T cells (Marrack et al., 1999) and
augmented clonal expansion and effector differentiation of
CD8+ T cells (Curtsinger et al., 2005) through cell-intrinsic
IFN-/ receptor signaling. Similarly, type I IFN responsive
ness in T cells was required in vivo for optimal clonal expansion
of antigen-specific CD8+ and CD4+ T cells during viral infec
tion (Kolumam et al., 2005; Havenar-Daughton et al., 2006;
Thompson et al., 2006) as well as for CD8+ T cell priming after
immunization with antigen and IFN- (Le Bon et al., 2006a).
B cell differentiation, antibody production, and isotype class
switching were also enhanced by type I IFN’s effects either di
rectly on B cells or indirectly via effects on T cells (Coro et al.,
2006; Le Bon et al., 2006b) and DCs (Le Bon et al., 2001).
Type I IFN also directly enhances the function of DCs,
which are central to the initiation of adaptive immune responses
(Steinman and Banchereau, 2007). IFN-/ induces DC matu
ration, up-regulates their co-stimulatory activity and enhances
their capacity to present or cross-present antigen (Luft et al.,
1998; Gallucci et al., 1999; Montoya et al., 2002). For example,
coinjection of IFN-/ plus antigen (Gallucci et al., 1999;
Le Bon et al., 2001, 2003) or injection of DC-targeted antigen in
combination with the IFN-/ inducer polyinosinic:polycyti
dylic acid (polyI:C; Longhi et al., 2009) stimulated CD8+ T cell
priming, humoral responses, and development of CD4+ Th1
responses in vivo. Recently, a subpopulation of DCs whose de
velopment depends on expression of the BATF3 transcription
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RESULTS
Early requirement for type I IFN
during the antitumor response
We previously showed that blockade of type I IFN signaling by
pretreatment of mice with the IFNAR1 (IFN-/ receptor 1)specific MAR1-5A3 mAb (Sheehan et al., 2006) abrogated
rejection of highly immunogenic sarcomas derived from
3-methylcholanthrene (MCA)–treated Rag2/ mice (termed
unedited tumors; Dunn et al., 2005). To dissect the temporal
requirements for IFN-/’s actions during the antitumor im
mune response, we treated WT mice with either MAR1-5A3
or isotype control GIR-208 mAb at different times after injec
tion of unedited H31m1 MCA sarcoma cells. Whereas H31m1

cells were rejected when transplanted into naive syngeneic WT
mice either left untreated or pretreated with GIR-208, the
tumors grew progressively in WT mice pretreated with MAR15A3 (Fig. 1 A). Similarly, MAR1-5A3 treatment on day 4 or 6
(relative to tumor injection at day 0) blocked rejection in >50%
of injected mice. In contrast, IFN-/ receptor blockade at later
time points did not inhibit rejection (Fig. 1 B and Fig. S1). In
parallel experiments, blockade of IFN- via treatment with neu
tralizing IFN-–specific H22 mAb (Schreiber et al., 1985) re
vealed a more prolonged requirement for the actions of IFN-
during H31m1 rejection (Fig. 1 C). Cohorts of mice were also
treated with a mixture of mAbs that deplete CD4+ and CD8+
cells and neutralize IFN- (GK1.5 [Dialynas et al., 1983],
YTS169.4 [Cobbold et al., 1984], and H22, respectively) to
broadly disrupt host immunity. In this group, progressively
growing tumors were observed in a substantial proportion of
mice treated as late as day 14 with the anti-CD4/CD8/IFN-
mAb cocktail (Fig. 1 D). Collectively, these data demon
strate that the obligate functions of type I IFN are required
only for initiating the immune response to tumors.
A tissue-restricted role for type I IFN
during tumor rejection
To characterize the critical host cells responding to type I IFN
during initiation of the antitumor response, we transplanted
H31m1 tumor cells and cells from a second unedited MCA
sarcoma, d38m2, into bone marrow chimeras with selective
IFN-/ sensitivity. These tumor cell lines were selected be
cause we previously showed that their rejection required type I
IFN responsiveness at the level of the
host (Dunn et al., 2005). As reported
previously, both cell lines were rejected
when transplanted into immunocom
petent WT mice but formed pro
gressively growing tumors in either
Rag2/ or Ifnar1/ mice (Fig. 2,
A and B). We now show that both
lines grew progressively in Ifnar1/ →
Ifnar1/ bone marrow chimeras and
Figure 2. Nonoverlapping host cell targets for IFN-/ and IFN- during tumor
rejection. (A–C) Control mice and the indicated bone marrow chimeras with selective
IFN-/ sensitivity (A and B) or IFN- sensitivity (C) in hematopoietic versus nonhematopoietic cells were injected s.c. with 106 H31m1
(A) or d38m2 (B and C) unedited MCA sarcoma cells, and growth was monitored. Data
are presented as mean tumor diameter ± SEM
over time or the percentage of tumor-positive
mice per group from two to three (A and B) or
five (C) independent experiments with group
sizes as indicated. Hematopoietic reconstitution of all Ifnar1/ and Ifngr1/ bone
marrow chimeras was confirmed by flow cytom
etry at the conclusion of each experiment.
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that innate immune cells represent the essential responsive cells
for the generation of protective antitumor immunity. Whereas
type I IFN–unresponsive mice showed a defect in the priming
of tumor-specific CTLs, reconstitution of IFN-/ sensitivity
in innate immune cells was sufficient to restore this deficit and
resulted in tumor rejection. Within the innate immune com
partment, we find no evidence of an essential role for NK cells
or for type I IFN sensitivity in granulocytes or macrophages,
but rather find that the actions of IFN-/ on DCs are re
quired for development of tumor immunity in vivo and play
an important role in promoting the capacity of CD8+ lineage
DCs to cross-present antigen to CD8+ T cells. These results
thus identify DCs and specifically CD8+ lineage DCs as key
cellular targets of type I IFN in the development of protective
adaptive immune responses to immunogenic tumors.

was not caused by incomplete hematopoietic reconstitution,
we confirmed normal cellularity and immune cell percent
ages in the spleen, demonstrated normal functional immune
reconstitution, and ruled out the presence of radio-resistant
tissue-resident leukocytes within the tumor environment
(Figs. S3–S5). These data not only establish an important role
for IFN- sensitivity in both hematopoietic and nonhemato
poietic cells during tumor rejection but also reveal a differ
ence between the broad cellular requirements for IFN- as
opposed to the tissue-restricted requirement for IFN-/
during elimination of the same tumor.
Innate immune cells are the critical targets of type I IFN
To examine the role of type I IFN’s actions on innate versus
adaptive immune cells, we generated mixed bone marrow
chimeras with selective type I IFN sensitivity within the
hematopoietic compartment. Reconstitution of lethally irradi
ated Ifnar1/ mice with a 4:1 mixture of Rag2/ and Ifnar1/
hematopoietic stem cells (HSCs) yielded mice with IFN-/
responsiveness solely in innate immune cells (Rag2/ +
Ifnar1/ → Ifnar1/ chimeras, hereafter referred to as innate
chimeras). Conversely, reconstitution of Ifnar1/ mice with
a 4:1 mixture of Rag2/ × Ifnar1/
double KO mice (Rag2/Ifnar1/)
and WT HSCs produced chimeras with
IFN-/–sensitive T and B lympho
cytes but a predominantly IFN-/–
insensitive innate immune compartment
(Rag2/Ifnar1/ + WT → Ifnar1/;
Figure 3. IFN-/ sensitivity within the
innate immune compartment is necessary
and sufficient for tumor rejection. Mixed
bone marrow chimeras with selective IFNAR1
expression in innate or adaptive immune cells
were generated by reconstitution of irradiated
Ifnar1/ mice with mixtures of HSCs as described in Results. (A) Splenocytes were isolated
from representative cohorts of control and
mixed chimeric mice at least 12 wk after reconstitution, and IFNAR1 staining was analyzed by flow cytometry. Shown are the
percentages of IFNAR1+ cells within the indicated immune cell subsets for 8–14 mice of
each type. Horizontal bars represent the mean.
(B–D) Control WT, Rag2/, and Ifnar1/ mice
and Ifnar1/ mixed chimeric mice were injected with 106 H31m1 (B), d38m2 (C), or F515
(D) tumor cells, and growth was monitored
over time. Data are presented as mean tumor
diameter ± SEM or the percentage or tumorpositive mice per group from two to three
independent experiments with group sizes as
indicated. WT mice treated with control or IFN-–
specific mAb were challenged with 106 F515
tumor cells, and growth was monitored
(D, bottom). Mean tumor diameter ± SEM for 7–10
mice/group from two experiments is shown.
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Ifnar1/ → Rag2/ chimeras (IFN-/ sensitivity only
in nonhematopoietic cells) but were rejected in WT → WT
chimeras and WT → Ifnar1/ chimeras (IFN-/ sensitivity
only in hematopoietic cells). These results thus extend, to two
additional tumors, our prior finding that type I IFN sensitivity
within the hematopoietic compartment is both necessary and
sufficient for tumor rejection (Dunn et al., 2005).
Because the rejection of immunogenic sarcomas also re
quires IFN- sensitivity within the host (Fig. S2), we wanted
to determine whether IFN-/ and IFN- were mediating
their effects by acting on the same host cell compartment.We
thus performed a similar set of experiments using chimeras
with selective host cell IFN- responsiveness. As expected,
d38m2 tumor cells grew progressively in Rag2/, Ifngr1/,
and Ifngr1/ → Ifngr1/ mice but were rejected in WT and
WT → WT hosts (Fig. 2 C).Tumor growth was also observed
in a significant fraction of Ifngr1/ → Rag2/ and WT →
Ifngr1/ chimeras, though the defect in these mice (which
selectively express the IFN- receptor in either nonhemato
poietic or hematopoietic cells, respectively) appeared less
severe than that in globally insensitive Ifngr1/ → Ifngr1/
chimeras. To ensure that tumor growth in the chimeric mice
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behavior of unedited MCA sarcoma cells (F515) that require
lymphocytes and IFN- but not host IFN-/ responsiveness
for their rejection. F515 tumor cells grew progressively when
injected into Rag2/ mice and WT mice treated with IFN-–
specific H22 mAb but were rejected in WT mice, WT mice
treated with isotype control PIP mAb, and Ifnar1/ hosts
(Fig. 3 D). Similar to Ifnar1/ mice, F515 cells were also re
jected in Ifnar1/ mixed chimeras of each type, verifying
functional reconstitution of the immune compartment. Third,
to rule out a potential hyperactive immunological state in these
reconstituted mice, we challenged Ifnar1/ mixed chimeras
and control mice with MCA sarcoma cells derived from WT
mice (1877). We have previously established that this tumor
grows progressively when transplanted into naive WT mice
(unpublished data). Similarly, these tumor cells grew progres
sively in Ifnar1/ mixed chimeras of each type (Fig. 4 C).
Sensitivity to type I IFN in innate immune cells is required
for the generation of tumor-specific CTL
To investigate the mechanism by which endogenous type I
IFN promoted host antitumor responses, we looked specifi
cally at the priming of tumor-specific T cells in WT and
Ifnar1/ mice after tumor challenge. Splenocytes from WT
hosts isolated 20 d after inoculation of H31m1 tumor cells
showed robust cytolytic activity against H31m1 targets after
in vitro restimulation (Fig. 5 A). In contrast, tumor-specific
killing was largely absent from splenocytes derived from
Ifnar1/ mice challenged with tumor cells. Similar
results were observed using another highly immuno
genic unedited MCA sarcoma (GAR4.GR1) or
using IFN- production as a readout (unpublished
data). To ask whether type I IFN sensitivity in in
nate immune cells was sufficient to generate tumorspecific immune responses, we used the mixed bone
marrow chimeras described previously (Fig. 3).
These experiments showed that IFN-/’s actions
on the innate immune compartment were indeed
both necessary and sufficient for development of
Figure 4. Normal hematopoietic reconstitution in
Ifnar1/ mixed bone marrow chimeras. (A) Spleens were
harvested from WT, Ifnar1/, or Ifnar1/ mixed chimeras
of each type (12 wk after reconstitution), and cell density
was determined. Horizontal bars represent the mean.
(B) Percentages of the indicated immune cell subsets were
measured by flow cytometry for WT, Ifnar1/, and Ifnar1/
mixed chimeras. Mean values (as a percentage of total
splenocytes) ± SEM for four to five mice/group are shown.
Cell populations were defined as follows: CD4+ T cells
(CD3+CD4+), CD8+ T cells (CD3+CD8+), B cells (B220+), NK cells
(DX5+CD3), DCs (CD11chi), and myeloid cells (CD11b+).
(C) WT-derived 1877 tumor cells were injected at a dose of
106 cells/mouse into WT, Ifnar1/, Rag2/, and Ifnar1/
mixed chimeras, and tumor growth was monitored over
time. Data represent the mean tumor diameter ± SEM for
three to eight mice/group. (A–C) Data are representative of
two independent experiments.
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adaptive chimeras). Control chimeras with responsiveness
in both innate and adaptive compartments (Rag2/ +
WT → Ifnar1/; innate + adaptive) or neither compartment
(Ifnar1/ → Ifnar1/; “neither”) were also generated. The
phenotypes of mixed chimeras generated using this ap
proach were confirmed by IFNAR1 staining of splenocyte
subsets (Fig. 3 A and Fig. S6).
When challenged with H31m1 or d38m2 cells, Rag2/
and Ifnar1/ control mice and globally unresponsive “nei
ther” chimeras developed progressively growing tumors. In
contrast, WT controls and pan-hematopoietic responsive in
nate + adaptive or WT → WT chimeras rejected the tumor
challenge (Fig. 3, B and C), consistent with our previous re
sults (Fig. 2). Importantly, H31m1 and d38m2 cells were re
jected in mixed chimeras with IFN-/ sensitivity only in
innate immune cells (i.e., innate chimeras) but grew progres
sively in chimeras with IFN-/ sensitivity largely re
stricted to the adaptive immune compartment (i.e., adaptive
chimeras). These findings demonstrate that the essential anti
tumor functions of type I IFN on host cells during tumor
rejection are selectively directed toward cells of the innate
immune compartment.
To confirm the functional hematopoietic reconstitution
of Ifnar1/ mixed chimeras, we performed three experi
ments. First, we confirmed the normal representation of vari
ous immune cell subsets within the spleens of mixed chimeric
mice (Fig. 4, A and B). Second, we assessed the in vivo growth

tumor-specific cytotoxicity (Fig. 5 B). In addition, treatment
of splenocytes from innate chimeras with blocking CD4- or
CD8-specific antibodies confirmed the importance of CD8+
cells for in vitro cytotoxicity (Fig. 5 C). These results demon
strate the selective importance of type I IFN on innate im
mune cells to induce tumor-specific CTL priming.

Figure 5. Impaired tumor-specific CTL priming in Ifnar1/ mice is
restored by IFN-/–responsive innate immune cells. (A) Splenocytes
from WT and Ifnar1/ mice were isolated 20 d after H31m1 tumor challenge (106 cells/mouse), co-cultured with IFN-–treated, irradiated
H31m1 cells, and 5 d later used as effectors in a cytotoxicity assay with
51Cr-labeled H31m1 targets. Specific killing activity (in percentage ± SEM)
at the indicated effector/target (E:T) ratios is shown for four to five mice
per group assayed in duplicate from three independent experiments.
(B) Splenocytes were harvested from the indicated chimeric mice 20 d
after injection of 106 H31m1 tumor cells and were treated as in A. Data
include representative results from three mice per group assayed in duplicate from two independent experiments. Splenocytes harvested from a
naive mouse and treated similarly served as a negative control. (C) Effector cells from H31m1-challenged innate chimeras were co-cultured at the
indicated effector/target ratios with 51Cr-labeled H31m1 targets in the
presence of 10 µg/ml control (PIP), anti-CD4 (GK1.5), or anti-CD8 (YTS169.4) mAbs. Data show representative results from three mice per group
assayed in duplicate from three independent experiments. Similar results
were obtained when effector cells from H31m1-injected WT mice were
used (not depicted). (B and C) Error bars represent SEM.
1994

Granulocytes and macrophages do not require
type I IFN sensitivity for tumor rejection
To test whether type I IFN sensitivity is required by granulo
cytes and macrophages for tumor rejection, we crossed
C57BL/6 strain LysM-Cre+ mice (Clausen et al., 1999) to
C57BL/6 Ifnar1f/f mice (Prinz et al., 2008; prepared by back
crossing 129 strain Ifnar1f/f mice >99% onto a C57BL/6 back
ground using a speed congenic approach). The resulting
LysM-Cre+Ifnar1f/f mice displayed complete IFNAR1 deletion
in peritoneal macrophages and PMNs and substantial deletion
of IFNAR1 in monocytes (66%) and splenic macrophages
(35%) but maintained undiminished IFNAR1 expression in
DCs, NK cells, T cells, and B cells (Fig. 7, A and B). Perito
neal macrophages from these mice were unresponsive to type
I IFN and failed to phosphorylate STAT1 after IFN- stimula
tion (Fig. 7 C). However, LysM-Cre+Ifnar1f/f mice still rejected
highly immunogenic unedited B6 strain 1969 sarcoma cells
similar to IFN-/–responsive Ifnar1f/f mice (Fig. 7 D). In
contrast, these tumor cells formed progressively growing
tumors in B6 strain Ifnar1/ control mice. Thus, protective
tumor immunity does not require type I IFN sensitivity in
granulocytes and at least some macrophage compartments.
CD8+ lineage DCs are important targets
of type I IFN’s actions
Having ruled out NK cells, PMNs, and certain macrophage
subsets as the critical type I IFN responsive cellular popula
tions, we turned our attention to DCs. We previously showed
that the selective absence of CD8+ lineage DCs in 129 strain
Batf3/ mice led to an impairment in tumor-specific CTL
priming and an inability to reject 129 strain H31m1 or 1773
unedited sarcoma cells (Hildner et al., 2008). We sub
sequently made similar observations using three other unedited
129 strain sarcoma cell lines (d38m2, d42m1, and GAR4.
GR1) that require IFNAR1 in host cells for rejection (un
published data). Given the effects of type I IFN in promoting
DC maturation, we hypothesized that DCs, and specifically
CD8+ lineage DCs, may be critical innate immune targets
Type I IFN effects during tumor rejection | Diamond et al.
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NK cells are not required for type I IFN–dependent
tumor rejection
Because NK cells have a host-protective function in some
tumor models and display enhanced cytotoxic activity in re
sponse to type I IFN, we investigated the role of NK cells
in the rejection of highly immunogenic sarcomas. We used
comparable unedited MCA sarcoma cells generated from

genetically pure C57BL/6 Rag2/ mice and naive WT
C57BL/6 mice as recipients because we could deplete NK
cells in C57BL/6 mice with the NK1.1-specific PK136 mAb
(Koo and Peppard, 1984). Similar to results with unedited
MCA sarcomas from 129/Sv mice, immune-mediated rejec
tion of two representative C57BL/6 strain unedited sarcomas
(1969 and 7835) required IFN-/ sensitivity at the level of
the host (Fig. 6, A and B). When PK136-treated WT mice
were injected with unedited C57BL/6 tumor cells, they
rejected these tumors with kinetics identical to control mice.
We confirmed NK cell depletion by (a) flow cytometry,
(b) the absence of ex vivo killing of YAC-1 targets by spleno
cytes from mAb-treated mice, and (c) the lack of in vivo
control of RMA-S tumor cell growth (Fig. 6, C–E). These
data therefore indicate that NK1.1+ NK cells are not
required for IFN-/–dependent rejection of unedited
MCA sarcomas.
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of type I IFN during tumor rejection. The following four sets
of experiments were performed to test this hypothesis.

IFN-/ signaling by DCs is required for rejection of
tumors. Second, we assessed tumor rejection in mice that
displayed a selective deletion of IFNAR1 in DCs. We crossed
the aforementioned C57BL/6 strain Ifnar1f/f mice to a spe
cific line of Itgax (CD11c)-Cre+ mice generated on a pure
C57BL/6 genetic background (Stranges et al., 2007). When
compared with the same cell populations from control mice
by flow cytometry, IFNAR1 was expressed in undiminished
levels in B cells, T cells, NK cells, macrophages, granulo
cytes, and plasmacytoid DCs (pDCs) from Itgax-Cre+Ifnar1f/f
mice (Fig. 8, A and B; and Fig. S8 A). In contrast, IFNAR1
expression was substantially reduced in CD8+ DCs, the
highly related CD103+ DCs, and CD4+ DCs from Itgax-Cre+
Ifnar1f/f mice (Fig. 8, A and B). The reduction in IFNAR1

Adoptive transfer of type I IFN–responsive DCs into
Ifnar1/ mice promotes induction of antitumor responses.
Third, we examined whether the adoptive transfer of CD11c+
cells isolated from the spleens of naive WT or Ifnar1/
mice into Ifnar1/ recipients promoted tumor resistance
in vivo. Whereas CD11c+ cells from WT mice induced

Figure 6. NK cell depletion does not abrogate IFN-/–dependent rejection of immuno
genic sarcomas. (A and B) C57BL/6 WT, Rag2/,
and Ifnar1/ mice and WT mice treated with
either PBS or anti-NK1.1 PK136 mAb were injected s.c. (106 cells/mouse) with 1969 (A) or 7835
(B) unedited MCA sarcoma cells, and growth was
monitored over time. Data are presented as mean
tumor diameter ± SEM of 4–13 (untreated) or 8
(treated) mice per group from at least two independent experiments. Error bars for Ifnar1/
mice reflect progressive growth of 1969 and 7835
tumors in 6/9 mice. (C) WT C57BL/6 mice were
treated with either PBS or PK136 mAb, and splenocytes were harvested 2 d later and analyzed by
flow cytometry using the NK cell markers DX5
and NKp46. Splenocytes were gated on CD3
cells, and the percentages of DX5+NKp46+ cells
are indicated. Similar results were found when
harvested at day 6 (not depicted). (D) WT C57BL/6
mice were treated with PBS or PK136 followed by
i.p. injection of 300 µg polyI:C 4 d later. After 24 h,
splenocytes were harvested and used as effectors in a standard 4-h cytotoxicity assay with
NK-sensitive YAC-1 targets. Specific lysis
(in percentage ± SEM) at the indicated effector/
target (E:T) ratios is shown for four mice/group
assayed in duplicate from two independent
experiments. (E) WT C57BL/6 mice were treated with PBS, PK136, or a mixture of anti-CD4 (GK1.5) and anti-CD8 (YTS-169.4) mAbs and injected s.c. with
105 RMA-S cells, and tumor growth was monitored over time. Mean tumor diameter ± SEM for three mice/group is shown, and data are representative of
two independent experiments.
JEM Vol. 208, No. 10
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DC subsets develop normally in the absence of IFNAR1.
First, we assessed whether Ifnar1/ mice displayed a defi
ciency in any DC populations. Analyses of splenic and LN
cells revealed no difference between the numbers of each DC
subset in WT and Ifnar1/ mice (Fig. S7). In addition, there
was no defect in the ability of Ifnar1/ DCs to expand in
vivo in response to flt3 (fms-like tyrosine kinase 3) ligand-Fc
treatment (not depicted). Thus, the absence of type I IFN
signaling did not affect the development of any DC subset.

expression corresponds to the selective expression of Cre
recombinase in these cell types as indicated by expression of
a bicistronic GFP gene that is contributed by the Itgax-Cre
mouse (Fig. S8 B). Both CD8+ and CD4+ DCs from ItgaxCre+Ifnar1f/f mice exhibited significantly decreased respon
siveness to type I IFN as detected by reduced accumulation
of pSTAT1 (Fig. 8 C) and by impaired up-regulation of
CD86 upon stimulation with IFN- (Fig. S8 C). In contrast,
T cells and macrophages in Itgax-Cre+Ifnar1f/f mice displayed
type I IFN responsiveness that was comparable with cells
from Ifnar1f/f mice. The selective nature of IFNAR1 deletion
and loss of function in DCs allowed us to examine whether
these cells were obligate targets of type I IFN during devel
opment of antitumor responses in vivo. Whereas unedited
B6 strain 1969 sarcoma cells were rejected in WT or Ifnar1f/f
mice, they formed progressively growing tumors in ItgaxCre+Ifnar1f/f mice with growth kinetics indistinguishable from
those in Ifnar1/ mice (Fig. 8 D). These results thus demon
strate that type I IFN sensitivity is specifically required by
DCs for development of host-protective tumor immunity.

Type I IFN enhances the cross-presenting activity of
CD8+ lineage DCs. Fourth, we assessed whether type I IFN
directly affected antigen cross-presentation by DCs in vitro
by culturing splenic DCs isolated from WT or Ifnar1/
mice with irradiated ovalbumin-loaded MHC class I–deficient
splenocytes and OT-I T cells. Total CD11c+ cells purified

from WT mice were more effective than Ifnar1/-derived
cells in inducing the proliferation of OT-I T cells (Fig. 9 A),
although this defect could be overcome at high doses of
antigen. Cross-presentation by WT CD11c+ cells was en
hanced by treatment with exogenous IFN- and inhibited
by the addition of MAR1-5A3 mAb that blocked the type I
IFN receptor on these cells (Fig. 9 B). When WT and
Ifnar1/ DCs were further purified into CD8+ and CD4+
subsets, the CD8+ DC subset was shown to be the critical
cross-presenting cell in this assay, and a more significant defi
cit was observed in the capacity of Ifnar1/ CD8+ DCs to
activate OT-I T cells (Fig. 9 C). Importantly, the CD8+
DCs from Itgax-Cre+Ifnar1f/f mice displayed an OVA antigen
cross-presentation defect that was virtually identical to
CD8+ DCs from Ifnar1/ mice (Fig. 10). Similar results
were also obtained when MHC mismatched, IFN-–insensitive
CMS-5-IC tumor target cells that were transduced with
an OVA-expressing retrovirus were used
as a source of antigen (Fig. S10). These
findings thus demonstrate that type I
IFN acts directly on CD8+ DCs to en
hance cross-presentation of antigen to
naive CD8+ T cells.
Figure 7. Granulocytes and macrophages do
not require type I IFN sensitivity for tumor
rejection. (A) IFNAR1 expression on peritoneal
macrophages, blood monocytes, PMNs, and
B cells was measured using flow cytometry in
Ifnar1f/f, LysM-Cre+Ifnar1f/f, and Ifnar1/ mice.
(B) Summary of IFNAR1 levels in the indicated
cellular subsets in LysM-Cre+Ifnar1f/f mice compared with Ifnar1f/f mice (expressed as a percentage of the mean fluorescence intensity [MFI]).
Cells were gated using the following markers:
macrophages (CD11b+F4/80+), PMNs (CD11b+
Gr1+), monocytes (CD115+CD11b+), B cells
(B220+), CD8+ DCs (CD8+Dec205+CD11chi),
CD4+ DCs (CD8Dec205CD11chiCD4+), pDCs
(B220+PDCA+CD11cint), T cells (CD3+), and NK cells
(NK1.1+). IFNAR1 expression was measured using
MAR1-5A3 mAb. Data represent at least three
mice from three independent experiments (**, P <
0.01). (C) Mature peritoneal macrophages from
LysM-Cre+Ifnar1f/f mice were untreated (gray) or
stimulated for 15 min with 10 ng/ml IFN-v4
(black), and pSTAT1 accumulation was measured
by flow cytometry. Histograms from a representative experiment are shown, with the bar graph
summarizing pSTAT1 levels (as percentage of
control Ifnar1f/f MFI) from two independent experiments. (B and C) Error bars represent SEM.
(D) Ifnar1f/f, LysM-Cre+Ifnar1f/f, and Ifnar1/
mice were injected s.c. with 106 1969 unedited
sarcoma cells. Mean tumor diameter ± SEM from
a representative experiment is shown, and the bar
graph shows the percentage of tumor-positive
mice per group from two independent experiments with indicated total group sizes.
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tumor-specific CTL priming (Fig. S9 A), Ifnar1/ CD11c+
cells did not. The transfer of WT CD11c+ cells also delayed
tumor growth but did not result in tumor rejection (Fig. S9 B).
In contrast, no effect on tumor growth was observed upon
transfer of CD11c+ cells derived from Ifnar1/ mice. This
difference was statistically significant (P = 0.03). These results
are consistent with our previous observation that transfer of
purified DC populations into Batf3/ mice results in only
partial reconstitution of the antitumor response, perhaps be
cause of issues of DC trafficking (Hildner et al., 2008).

Ar ticle

IFN during tumor rejection are distinguishable from those
of IFN- both temporally and functionally, and they repre
sent an important step toward mapping the critical molecular
pathways involved in cancer immunoediting.
Functionally active type I IFN receptors are expressed on
nearly all nucleated cells, and previous studies documented
effects of type I IFN on many immunologically relevant cell
types (such as T cells, NK cells, and DCs) that theoretically
should enhance the immune elimination of tumors (Dunn
et al., 2006). Thus, it was surprising to find an essential func
tional requirement for type I IFN in only a single cellular
compartment, namely DCs, during the development of pro
tective tumor-specific immune responses in vivo. As further
documented in vitro, type I IFN enhances the function of
the CD8+ DC subset, which in a previous study was shown
to play a critical role in the development of tumor- and virusspecific immune responses through its capacity to cross-present
antigen to CD8+ T cells (Hildner et al., 2008). These cells,
Figure 8. DCs specifically require type I IFN
sensitivity for tumor immunity in vivo.
(A) IFNAR1 expression on splenic CD8+ DCs,
CD4+ DCs, pDCs, LN CD103+ DCs, and dermal DCs
was measured using flow cytometry in Ifnar1f/f,
Itgax-Cre+Ifnar1f/f, and Ifnar1/ mice. (B) Summary of IFNAR1 levels on the indicated cellular
subsets in Itgax-Cre+Ifnar1f/f mice compared with
Ifnar1f/f mice (expressed as a percentage of control
mean fluorescence intensity [MFI]). Cells were gated
as follows: CD8+ DCs (CD8+Dec205+CD11chi),
CD103 DCs (CD8Dec205+CD11chiCD103+),
CD4+ DCs (CD8Dec205CD11chiCD4+),
dermal DCs (CD8CD11chiCD103), pDCs
(B220+PDCA+CD11cint), B cells (B220+),
T cells (CD3+), NK cells (NK1.1+), macrophages
(CD11b+F4/80+), and blood PMNs (CD11b+Gr1+).
IFNAR1 expression was measured using the
MAR1-5A3 mAb. Data represent three to five
mice from at least three independent experiments. (**, P < 0.01). (C) Splenocytes from ItgaxCre+Ifnar1f/f mice were untreated (gray) or
stimulated for 15 min with 10 ng/ml IFN-v4
(black), and pSTAT1 accumulation in CD8+ and
CD4+ DCs was measured by flow cytometry. Histograms show a representative experiment, and
the bar graph summarizes results from four independent experiments (**, P < 0.01). (B and C) Error
bars represent SEM. (D) C57BL/6 WT, Ifnar1/,
Ifnar1f/f, and Itgax-Cre+Ifnar1f/f mice were injected s.c. with 106 1969 unedited sarcoma cells.
Mean tumor diameter ± SEM from a representative experiment is shown, and the bar graph
shows a summary of the percentage of tumorpositive mice per group from three independent
experiments with indicated groups sizes (P <
0.001 [WT vs. Ifnar1/] and P < 0.001 [Ifnar1f/f
vs. Itgax-Cre+Ifnar1f/f]) using the Student’s t test
at day 23. Comparisons of Ifnar1/ versus ItgaxCre+Ifnar1f/f or WT versus Ifnar1f/f were not significantly different.
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DISCUSSION
Previous work from our laboratory and others has shown that
naturally occurring, host-protective immune responses against
many highly immunogenic tumors require the obligate par
ticipation of endogenously produced type I IFN (Dunn et al.,
2005; Swann et al., 2007). Although these earlier studies
pointed to hematopoietic cells as the physiologically relevant
targets of type I IFN action, they neither identified the spe
cific cell populations affected nor defined the functions that
they performed. The current study was undertaken to eluci
date the role of endogenously produced type I IFN in driving
host-protective, antitumor responses. Herein we demonstrate
that type I IFN exerts its activity early during the develop
ment of the antitumor response, that its major physiological
function is directed selectively toward a single host cell popu
lation (i.e., DCs), and that, at least in part, it functions to en
hance the capacity of CD8+ DCs to cross-present antigen to
CD8+ T cells. These data thus reveal that the actions of type I

which are dependent on the BATF3 transcription factor for
their development, were originally identified as the CD8+
DCs that resided in lymphoid organs; yet subsequent work
showed that they are closely related to another small DC subset
residing in peripheral tissues that lack CD8 but express
CD103 (Hildner et al., 2008; Ginhoux et al., 2009; Edelson
et al., 2010). Although we find herein that optimal crosspresenting activity of CD8+ DCs occurs only in response to
type I IFN, our results do not exclude a requirement for type
I IFN in regulating other DC populations such as CD4+ DCs.
Thus, we conclude that the CD8+ DC subset represents
one innate immune cell population that displays an obligate
requirement for type I IFN to perform its function in the anti
tumor response.

Support for this conclusion comes directly from the find
ing that bone marrow chimeric mice with selective recon
stitution of type I IFN sensitivity in the innate immune
compartment generated tumor-specific CTL and rejected
immunogenic tumor cells, whereas the direct actions of type
I IFN on T and B lymphocytes contributed little to the anti
tumor response. It is important to stress that whereas the re
sults of our analyses clearly show that T cells are not the
essential type I IFN–sensitive cellular population, immune
elimination of tumors nevertheless requires both CD4+
and CD8+ T cells. The lack of a requirement for type I IFN
responsiveness in T lymphocytes contrasts with results
from studies of CD8+ T cell priming and clonal expansion
in the settings of viral infection or protein immunization
Figure 10. Impaired antigen cross-presentation in
CD8+ DCs from Itgax-Cre+Ifnar1f/f mice. CD8+ DCs
were isolated from Ifnar1f/f, Itgax-Cre+Ifnar1f/f, and Ifnar1/
mice and incubated with OT-I T cells labeled with cell proliferation dye and 12,500 ovalbumin-loaded MHC class I/
splenocytes. Dilution of the cell proliferation dye was
measured 3 d later. Data represent one of at least two
independent experiments with similar results.
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Figure 9. Type I IFN sensitivity in CD8+ DCs enhances antigen cross-presentation. (A) CD11c+ cells were isolated from the spleens of WT or
Ifnar1/ mice and co-cultured with the indicated number of irradiated, ovalbumin-loaded MHC class I/ splenocytes and CFSE-labeled OT-I T cells.
After a 3-d incubation, proliferation of OT-I T cells was determined by CSFE dilution. Histograms represent CFSE levels in the CD8+ T cell population, with
the percentage of cells in the indicated gate noted. (B) WT and Ifnar1/ CD11c+ cells or WT CD11c+ cells incubated with exogenous 1,000 U/ml IFN- or
5 µg/ml IFNAR1-specific MAR1-5A3 mAb were treated as in A at a dose of 25,000 MHC class I/ splenocytes. (C) Purified CD8+ and CD4+ DC subsets
isolated from WT or Ifnar1/ mice were treated as in A with the indicated number of ovalbumin-loaded MHC class I/ splenocytes. Data represent one
of at least two independent experiments with similar results.
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we focused our attention on DCs as likely innate immune
targets of type I IFN’s actions. Although type I IFN is a strong
inducer of DC maturation (Luft et al., 1998; Gallucci et al.,
1999; Montoya et al., 2002), the specific role of this cellular
subset in the generation of protective antitumor responses has
been difficult to establish. Some studies have indeed impli
cated bone marrow–derived cells in the cross-presentation
of tumor-associated antigen (Huang et al., 1994), whereas
others have argued that direct priming may additionally be
involved (Ochsenbein et al., 2001; Wolkers et al., 2001).
Moreover, although the CD8+ DC subset is particularly
adept at antigen cross-presentation, evidence also exists that
other non-DC immune subsets as well as nonhematopoietic
stromal cells might be capable of cross-presenting exogenous
antigen in some circumstances (Ackerman and Cresswell,
2004; Heath et al., 2004; Spiotto et al., 2004).
The generation of mice lacking the transcription factor
BATF3 provided a useful mechanism to study DC crosspresentation in vivo because these mice have a cell-intrinsic
defect in the development of CD8+ DCs but normal repre
sentation and function of the remaining DC subsets as well as
other hematopoietic lineages (Hildner et al., 2008). Highly
immunogenic MCA sarcoma cells, which are rejected in WT
mice, formed progressively growing tumors in Batf3/ mice
and displayed growth kinetics comparable with those in lym
phocyte-deficient Rag2/ hosts (Hildner et al., 2008), a re
sult which we have corroborated in the current study. In
addition, the defect in Batf3/ mice correlated with a lack of
tumor-specific CTL priming (Hildner et al., 2008). These
findings therefore demonstrated that cross-priming by CD8+
lineage DCs is critical for tumor rejection, although they do
not address the nature of the innate immune signals necessary
for activation, migration, and in vivo function of these cells.
The importance of such stimuli is clear because crosspresentation without activation can lead to tolerance rather than
immunity (Steinman et al., 2003; Melief, 2008). A better
understanding of this process could provide insight into the
mechanisms that progressively growing tumors use to escape
immune control.
We show in this study that type I IFN enhances the crosspresentation of cell-associated antigen to naive CD8+ T cells
via direct actions on CD8+ lineage DCs. When taken to
gether with data demonstrating that (a) type I IFN promotes
tumor-specific CTL priming, (b) type I IFN acts on innate
immune cells to mediate its antitumor effects, (c) IFN-/–
responsive CD11c+ cells partially reconstitute in vivo CTL
priming in Ifnar1/ mice, (d) CD8+ lineage DCs are re
quired for CTL priming and tumor rejection, and (e) selective
deletion of IFNAR1 in DCs abrogates tumor rejection, the
collective evidence supports a host-protective function involv
ing direct actions of type I IFN on CD8+ lineage DCs.
The mechanism responsible for type I IFN’s enhancement
of CD8+ DC cross-priming remains to be determined. Type
I IFN may induce multiple effects on the CD8+ lineage DCs,
including the modulation of antigen capture or processing,
peptide shuttling and MHC loading, MHC class I and/or
1999
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(Kolumam et al., 2005; Le Bon et al., 2006a). Yet, it was
noted in these studies that during infection-induced clonal
expansion, the relative importance of type I IFN’s actions on
CD8+ T cells depended on the specific microbial pathogen
used (Thompson et al., 2006), with T cell expansion during
lymphocytic choriomeningitis virus infection showing a
profound dependence on type I IFN, but less prominent im
pairments occurring when other viruses were used. In addi
tion, another study reported no change in the generation of
antigen-specific CTL in mice lacking the type I IFN receptor
in the T cell compartment after immunization with peptide
and IC31 (Pilz et al., 2009), an adjuvant based on Toll-like
receptor 9 signaling. Given these data, it was suggested that
distinct inflammatory environments might evoke expansion
of CD8+ T cell subsets that differ in their dependence on
type I IFN for survival and function and that such environ
mental cues may include the levels of type I IFN and other
signals that stem from innate cells (Stetson and Medzhitov,
2006; Thompson et al., 2006). Little is known about the
magnitude and localization of type I IFN production (and
that of other inflammatory cytokines) during immune re
sponses to tumors, and further investigation is warranted.
To further define the target cells within the innate im
mune compartment affected by type I IFN, we bred Ifnar1f/f
mice to LysM-Cre mice, an accepted method of deleting
floxed target genes in non-DC myeloid cells (Clausen et al.,
1999). The resulting mice exhibited nearly complete deletion
of IFNAR1 in peritoneal macrophages and PMNs and re
duced levels of IFNAR1 in other myeloid populations in
cluding monocytes and splenic macrophages. Nevertheless,
targeting myeloid cell IFNAR1 to the levels observed did not
compromise antitumor immunity. These findings exclude a
prominent role for granulocyte type I IFN sensitivity in our
tumor system contrasting with data in the B16 melanoma
model, suggesting that direct effects of endogenous IFN-
on tumor-infiltrating neutrophils are responsible for its anti
tumor functions by suppressing expression of proangiogenic
factors (Jablonska et al., 2010). With respect to the contribu
tions of monocyte/macrophage subsets, more work is needed
to define whether specific populations contribute to tumor
immunity in the MCA sarcoma model, whether they are the
same populations targeted in the LysM-Cre mouse, and which
functions, if any, are influenced by type I IFN. Others have
nonetheless shown that LysM-Cre+Ifnar1f/f mice exhibit a
clear phenotype during experimental autoimmune encepha
lomyelitis despite observing similar partial reductions of
IFNAR1 in myeloid populations (Prinz et al., 2008).
LysM-Cre+Ifnar1f/f mice display undiminished IFNAR1 ex
pression in DCs. Thus, LysM-Cre+Ifnar1f/f mice also serve as
a control to support the conclusion that IFNAR1 is required
predominantly in DCs and that tumor immunity remains in
tact when IFNAR1 is genetically deleted in non-DC innate
immune compartments.
Given the findings that adaptive immune cells, granulo
cytes, and macrophages function independently of type I IFN
and that NK cells do not play an obligate role in our system,
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MATERIALS AND METHODS
Mice. 129/SvPas WT mice were purchased from Charles River. 129/SvEv
Rag2/, C57BL/6 WT, and C57BL/6 Rag2/ mice were obtained from
Taconic. C57BL/6 strain Itgax-Cre+/ (GFP) mice (Stranges et al., 2007) and
LysM-Cre+/ mice (Clausen et al., 1999) were obtained from the Jackson
Laboratory. 129/Sv strain Ifnar1/ and Ifngr1/ were as described previ
ously (Dunn et al., 2005). Ifnar1f/f mice were as described previously
(Kamphuis et al., 2006). Both Ifnar1f/f and Ifnar1/ mice were backcrossed
onto the C57BL/6 background by speed congenic analysis (>99.7% purity).
129/Sv Rag2/Ifnar1/ mice were generated by intercrossing Rag2/
and Ifnar1/ mice. OT-I transgenic mice on a Rag1/ background were
obtained through the National Institute of Allergy and Infectious Diseases
Exchange Program, National Institutes of Health (C57BL6-Tg(OT-I)RAG1tm1Mom 004175; Mombaerts et al., 1992; Hogquist et al., 1994).
C57BL/6 MHC class I–deficient Kb/Db/2m/ mice (Lybarger et al.,
2003) were a gift from H. Virgin and T. Hansen (Washington University in
St. Louis, St. Louis, MO). 129/SvEv background Batf3/ mice have been
described previously (Hildner et al., 2008). Mice were maintained in a spe
cific pathogen-free facility in accordance with American Association for
Laboratory Animal Science guidelines, and all protocols involving laboratory
animals were approved by the Washington University Animal Studies Com
mittee (School of Medicine, Washington University in St. Louis).
Tumor transplantation. MCA-induced fibrosarcomas were derived from
129/Sv strain Rag2/ or WT mice and C57BL/6 strain Rag2/ mice as de
scribed previously (Shankaran et al., 2001; Dunn et al., 2005; Koebel et al.,
2007). The GAR4 tumor, derived from an MCA-treated 129/Sv Ifngr1/
Ifnar1/ mouse, as well as IFNGR1-resconstituted GAR4.GR1 cells and
IFNAR1-reconstituted GAR4.AR1 cells have been described previously
(Dunn et al., 2005). RMA-S is an MHC class I–deficient variant of the
C57BL/6 strain T lymphoma RMA (Kärre et al., 1986). Tumor cells were
propagated in vitro and injected s.c. in a volume of 150 µl endotoxin-free PBS
into the shaved flanks of recipient mice as described previously (Dunn et al.,
2005). Injected cells were >90% viable as assessed by trypan blue exclusion.
Tumor size was measured on the indicated days and is presented as the mean
of two perpendicular diameters. When calculating percent tumor growth,
mice with tumors >6 mm in diameter were considered positive.
Antibody treatment. For IFN-/ receptor blockade, mice were injected
i.p. with a single 2.5-mg dose of IFNAR1-specific MAR1-5A3 mAb
(Sheehan et al., 2006) or GIR-208 isotype control mAb as described previ
ously (Dunn et al., 2005). For IFN- neutralization, 750 µg of IFN-–
specific H22 mAb (Schreiber et al., 1985) or PIP isotype control mAb was
injected i.p. followed by a 250-µg dose every 7 d. Broad immunodepletion
was achieved by i.p. administration of a mixture of anti-CD4 GK1.5 mAb
(Dialynas et al., 1983), anti-CD8 YTS-169.4 mAb (Cobbold et al., 1984),
and IFN-–specific H22 mAb. For this regimen, an initial dose of 750 µg of
each mAb or of the control PIP mAb was followed by 250 µg of each every
7 d as described previously (Koebel et al., 2007). NK cell depletion was
achieved in C57BL/6 mice by i.p. injection of 200 µg anti-NK1.1 PK136 mAb
(Koo and Peppard, 1984; BioLegend) on days 2, 0, and 2 (relative to tumor
injection) and 100 µg every 5 d.
Generation of bone marrow chimeras. Recipient mice were irradiated
with a single dose of 9.5 Gy and reconstituted with donor HSCs isolated
from embryonic day (E) 14.5 fetal livers or 5-fluorouracil (5-FU)–treated
adult bone marrow as described previously (Christensen et al., 2004; Dunn
et al., 2005). For harvest of fetal liver cells (FLCs), embryos were extracted
at E14.5, livers were removed, washed in sterile endotoxin-free PBS, and
homogenized through a cell strainer using a syringe plunger. 5-FU–treated
bone marrow was isolated 4–5 d after treatment of donor mice with
150 mg/kg 5-FU by i.p. injection. Cells were injected i.v. at a dose of 5 × 106
(FLCs) or 106 (5-FU–treated bone marrow) cells/mouse in 200 µl PBS.
Total cell dose was determined by titration of FLCs (Fig. S3) or based on prior
data (Dunn et al., 2005). For mixed chimeras, a 4:1 cell ratio was selected
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co-stimulatory molecule expression, cellular migration, sur
vival, or the induction of secondary cytokines/chemokines.
Although current understanding of the cell biology of crosspresentation is incomplete, some data indicate that heightened
or altered antigen processing, rather than better antigen cap
ture, underlies the ability of the CD8+ DCs to efficiently
cross-present antigen (Dudziak et al., 2007; Melief, 2008). Inter
estingly, a recent study suggested that steady-state produc
tion of low levels of IFN- promotes antigen presentation by
DCs to both CD8+ and CD4+ T cells via up-regulation of heat
shock protein 70, which boosts formation of MHC–peptide
complexes (Zietara et al., 2009). Another recent study dem
onstrated that type I IFN contributes to cross-presentation
by enhancing antigen retention and survival of CD8+ DCs
(Lorenzi et al., 2011). Additional mechanisms must be in
volved because baseline antigen presentation (in the presence
of low-level IFN-) induces cross-tolerance in the absence of
DC activation triggered by inflammatory signals such as en
hanced type I IFN production (Melief, 2008). The presence
of other inflammatory stimuli, which may collaborate with
type I IFN to activate CD8+ DCs, is suggested by detection
of residual low-level priming in the absence of type I IFN
signaling and the somewhat more robust tumor growth
in Batf3/ mice (lacking CD8+ DCs) compared with
Ifnar1/ mice (containing normal numbers of type I IFN–
unresponsive CD8+ DCs). The involvement of other in
flammatory stimuli and their influence on type I IFN’s
effects remain to be investigated.
Exogenous administration of recombinant IFN- has
shown efficacy in the treatment of human cancer patients
(Belardelli et al., 2002). However, despite many years of clin
ical use, surprisingly little is known regarding its mechanism
of action in this setting and the reason IFN- treatment is
effective in only a subset of patients. A host immunostimu
latory mechanism is likely given the correlation between
favorable responses to systemic IFN- and the appearance
of autoimmune sequelae in metastatic melanoma patients
(Gogas et al., 2006). Animal studies have also confirmed that type
I IFN activity on host cells, rather than actions on the tumor,
mediate the protective effect of IFN-/ administration
(Belardelli et al., 2002). Whereas current treatments generally
involve systemic injection of high-dose IFN-, it is possible
that more targeted therapy based on a better understanding of
the relevant underlying mechanism of action of type I IFN
will enhance therapeutic efficacy while reducing undesirable
side effects.
In summary, the findings made herein reveal that DCs
represent the major targets of type I IFN actions during the
induction of spontaneous tumor-specific CD8+ T cell re
sponses and that these responses result, at least in part, from
an enhanced capacity of CD8+ DCs to cross-present anti
gen to CD8+ T cells. These findings provide a strong ratio
nale for future studies aimed at elucidating the precise DC
functions that are regulated by type I IFN that ultimately
promote development of naturally occurring or therapeutic
immune responses to cancer.
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based on testing of different mixing ratios (Fig. S6). Animals were main
tained on trimethoprim-sulfamethoxazole (Hi-Tech Pharmacal) antibiotic
water prepared as described previously (Dunn et al., 2005) for 4 wk after
irradiation, and tumor transplantation of chimeric mice was performed at least
12 wk after reconstitution. Hematopoietic reconstitution of all animals was
verified by FACS staining of splenocytes at the completion of tumor trans
plantation experiments. Similar experimental results were obtained with mice
reconstituted using FLCs or 5-FU–treated bone marrow as donor cells.

Tumor-specific CTL killing assay. Spleens were harvested from mice
20 d after tumor implantation, and single cell suspensions were prepared by
homogenization using frosted glass slides. 4 × 107 splenocytes were cultured
with 2 × 106 IFN-–treated, irradiated (100 Gy) tumor cells. 5 d later, the
cells were harvested and used as CTL effector cells in a standard 4-h 51
Cr-release cytotoxicity assay that used tumor cell targets seeded at 10,000
cells/well and pretreated with 100 U/ml IFN- for 48 h. For blocking
assays, 10 µg/ml anti-CD8 (YTS-169.4), anti-CD4 (GK1.5), or control mAb
(PIP) was added to the cell culture of effector and target cells. Percent spe
cific killing was defined as (experimental condition cpm  spontaneous
cpm)/(maximal (detergent) cpm  spontaneous cpm) × 100.
NK cell cytotoxicity assay. Splenocytes were isolated from mice treated
with 300 µg polyI:C (Sigma-Aldrich) by i.p. injection 24 h prior and were
used as effector cells with 5,000 51Cr-labeled YAC-1 tumor targets. Percent
specific killing was assessed after 4-h coincubation. Each sample was assayed
in duplicate, and experiments were performed at least twice.
Adoptive transfer of CD11c+ cells. Splenic CD11c+ cells from naive WT
and Ifnar1/ mice (10 mice/group) were positively selected by MACS
(purity >90%) using CD11c microbeads (Miltenyi Biotec). 2 × 106 CD11c+
cells were mixed with 2 × 105 unedited MCA sarcoma cells (GAR4.GR1)
in endotoxin-free PBS and injected s.c. in a volume of 200 µl into the flanks
of Ifnar1/ mice at day 0. 3 d later, 2 × 106 CD11c+ cells were injected s.c.
around the site of tumor implantation.
Antigen cross-presentation assay. DC cross-presentation of antigen to
CD8+ OT-I T cells was assessed as previously described (Hildner et al.,
2008). In brief, spleens from naive WT or Ifnar1/ mice were digested with
collagenase B (Roche) and DNase I (Sigma-Aldrich), and cellular subpopu
lations were isolated by MACS purification (Miltenyi Biotec). Total CD11c+
DCs were obtained by negative selection using B220, Thy1.2, and DX5 micro
beads followed by positive selection with CD11c microbeads. CD8+ DCs
were recovered by B220, Thy1.2, DX5, and CD4 negative selection, fol
lowed by CD8 positive selection. CD4+ DCs were isolated by B220,
JEM Vol. 208, No. 10

Online supplemental material. Fig. S1 shows the kinetics of tumor
growth in mice treated with blocking IFNAR1-specific mAb. Fig. S2
demonstrates the importance of host IFN- sensitivity for rejection of
unedited sarcomas. Fig. S3 presents a titration of FLCs for generation of
bone marrow chimeras. Figs. S4 and S5 show the normal functional im
mune reconstitution of Ifngr1/ bone marrow chimeras (Fig. S4) and the
absence of radio-resistant, tissue-resident leukocytes in the tumors of these
mice (Fig. S5). Fig. S6 shows a determination of the HSC mixing ratio
used to generate mixed bone marrow chimeras. Fig. S7 shows an analysis of
DC subsets in Ifnar1/ mice. Fig. S8 shows further characterization of the
Itgax-Cre+Ifnar1f/f mice. Fig. S9 shows adoptive transfer experiments of WT
and Ifnar1/ CD11c+ cells into Ifnar1/ recipient mice. Fig. S10 shows
decreased cross-presentation by CD8+ DCs from Itgax-Cre+Ifnar1f/f mice
compared with Ifnar1f/f mice using retrovirally transduced tumor cells as a
source of antigen. Online supplemental material is available at http://www
.jem.org/cgi/content/full/jem.20101158/DC1.
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